Medpace Holdings Inc (MEDP)
Official siteHEALTHCARE • DIAGNOSTICS & RESEARCH • NASDAQ
Market Cap: $18.29B
Last updated: Nov 17, 2026 at 11:06 AM ET
Medpace Holdings Inc (MEDP) Stock Forecast
Analysts expect Medpace Holdings (MEDP) to earn $18.36 per share in the fiscal year ending Dec 31, 2026, on revenue of $2.85B. Of 14 analysts, 2 rate the stock Buy or Strong Buy, 11 Hold and 1 Sell or Strong Sell, for a consensus of Hold. Over the last 30 days, 10 estimates for the fiscal year ending Dec 31, 2026 were revised up and 0 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 14 ratings average 2.86, inside the Hold band from 2.5 up to 3.5. Buy and Strong Buy make up 14% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 1 | 7.1% |
| Buy | 1 | 7.1% |
| Hold | 11 | 78.6% |
| Sell | 1 | 7.1% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Hold
- Total analysts
- 14
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus rises 8.1% and revenue estimates rise 6.0%.
- Fiscal year ending Dec 31, 2026
- $18.36
- EPS consensus, revenue $2.85B
- Fiscal year ending Dec 31, 2027
- $19.85
- EPS consensus, revenue $3.02B
- Next report
- Feb 8, 2027
- Estimated
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $18.36 | $18.11 to $18.92 | 11 | $2.85B | $2.84B to $2.86B | 13 |
| Dec 31, 2027 | $19.85 | $19.30 to $20.35 | 11 | $3.02B | $2.86B to $3.08B | 13 |
Quarterly Estimates
The EPS consensus falls from $4.93 for the quarter ending Dec 31, 2026 to $4.66 for the quarter ending Mar 31, 2027.
EPS range
Revenue range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $4.93 | $4.67 to $5.20 | 14 | $732.76M | $695.80M to $761.25M | 14 |
| Mar 31, 2027 | $4.66 | $4.50 to $4.91 | 7 | $726.89M | $713.67M to $742.22M | 8 |
Estimate Revisions
Across the 2 periods below, the last 30 days brought 19 upward and 1 downward EPS revisions. Raises outnumber cuts in every period.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 10 | 0 |
| Fiscal year ending Dec 31, 2027 | 9 | 1 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has risen 3.7% from $17.70.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | $18.36 | $17.72 | $17.70 | $17.70 | $17.70 | +3.7% |
| Fiscal year ending Dec 31, 2027 | $19.85 | $19.32 | $19.31 | $19.31 | $19.31 | +2.8% |
| Quarter ending Mar 31, 2027 | $4.66 | $4.59 | $4.61 | $4.61 | $4.61 | +1.0% |
Frequently Asked Questions About MEDP
What is the MEDP stock forecast?
Consensus analyst estimates put Medpace Holdings's EPS at $18.36 for the fiscal year ending Dec 31, 2026, on revenue of $2.85B. The consensus rating from 14 analysts is Hold.
How do analysts rate MEDP stock?
Of 14 analysts covering Medpace Holdings, 1 rates it Strong Buy, 1 Buy, 11 Hold, 1 Sell and 0 Strong Sell, for a consensus of Hold.
What EPS do analysts expect from MEDP next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is $18.36, with estimates from $18.11 to $18.92 from 11 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is $19.85, with estimates from $19.30 to $20.35 from 11 analysts.
What revenue do analysts expect from Medpace Holdings next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $2.85B, with estimates from $2.84B to $2.86B. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $3.02B, with estimates from $2.86B to $3.08B.
How many analysts cover MEDP?
14 analysts rate Medpace Holdings stock, and 11 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
MEDP pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors